251 related articles for article (PubMed ID: 31888549)
1. Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis.
Shinkai A; Saito W; Hashimoto Y; Ishida S
BMC Ophthalmol; 2019 Dec; 19(1):267. PubMed ID: 31888549
[TBL] [Abstract][Full Text] [Related]
2. Potential Effects of Hormone Therapy in Type 2 Idiopathic Macular Telangiectasia.
Wolf-Schnurrbusch UEK; Leung I; Sallo FB; Clemons TE; Chew EY; Bird AC; Peto T;
Ophthalmic Res; 2018; 60(1):38-42. PubMed ID: 28903123
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen induced maculopathy presenting like macular telangiectasia type 2 in a patient with breast cancer.
Ansari Astaneh MR; Shokoohi Rad S; Ghavami Shahri SH; Heidarzadeh HR
J Oncol Pharm Pract; 2023 Mar; 29(2):489-492. PubMed ID: 35730198
[TBL] [Abstract][Full Text] [Related]
4. OCT Angiography Findings of Tamoxifen Retinopathy: Similarity with Macular Telangiectasia Type 2.
Lee S; Kim HA; Yoon YH
Ophthalmol Retina; 2019 Aug; 3(8):681-689. PubMed ID: 31068263
[TBL] [Abstract][Full Text] [Related]
5. Crystalline deposits in the macula - tamoxifen maculopathy or macular telangiectasia?
Rijal RK; Nakhwa C; Sindal MD
Nepal J Ophthalmol; 2014; 6(2):227-9. PubMed ID: 25680254
[TBL] [Abstract][Full Text] [Related]
6. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy.
Ooto S; Hangai M; Takayama K; Arakawa N; Tsujikawa A; Koizumi H; Oshima S; Yoshimura N
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5541-50. PubMed ID: 21642620
[TBL] [Abstract][Full Text] [Related]
7. OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study.
Runkle AP; Kaiser PK; Srivastava SK; Schachat AP; Reese JL; Ehlers JP
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3683-3689. PubMed ID: 28727884
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen Retinopathy and Macular Telangiectasia Type 2: Similarities and Differences on Multimodal Retinal Imaging.
Hess K; Park YJ; Kim HA; Holz FG; Charbel Issa P; Yoon YH; Tzaridis S
Ophthalmol Retina; 2023 Feb; 7(2):101-110. PubMed ID: 35948211
[TBL] [Abstract][Full Text] [Related]
9. Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density.
Chin EK; Kim DY; Hunter AA; Pilli S; Wilson M; Zawadzki RJ; Werner JS; Park SS
Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4459-70. PubMed ID: 23716628
[TBL] [Abstract][Full Text] [Related]
10. Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8.
Heeren TFC; Chew EY; Clemons T; Fruttiger M; Balaskas K; Schwartz R; Egan CA; Charbel Issa P;
Ophthalmology; 2020 Nov; 127(11):1539-1548. PubMed ID: 32586743
[TBL] [Abstract][Full Text] [Related]
11. FLUORESCENCE LIFETIME PATTERNS IN MACULAR TELANGIECTASIA TYPE 2.
Solberg Y; Dysli C; Wolf S; Zinkernagel MS
Retina; 2020 Jan; 40(1):99-108. PubMed ID: 30664123
[TBL] [Abstract][Full Text] [Related]
12. Epiretinal Neovascularization: A Novel OCT Angiography Finding in Macular Telangiectasia Type 2.
Ayachit AG; Reddy LU; Joshi S; Ayachit GS
Ophthalmol Retina; 2019 Jun; 3(6):516-522. PubMed ID: 31174674
[TBL] [Abstract][Full Text] [Related]
13. Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9.
Pauleikhoff L; Heeren TFC; Gliem M; Lim E; Pauleikhoff D; Holz FG; Clemons T; Balaskas K; ; Egan CA; Charbel Issa P
Am J Ophthalmol; 2021 Aug; 228():27-34. PubMed ID: 33775659
[TBL] [Abstract][Full Text] [Related]
14. Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography.
Pauleikhoff D; Gunnemann F; Book M; Rothaus K
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1381-1392. PubMed ID: 31093765
[TBL] [Abstract][Full Text] [Related]
15. Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography.
Toto L; Di Antonio L; Mastropasqua R; Mattei PA; Carpineto P; Borrelli E; Rispoli M; Lumbroso B; Mastropasqua L
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT268-76. PubMed ID: 27409482
[TBL] [Abstract][Full Text] [Related]
16. Pseudocystic foveal cavitation in tamoxifen retinopathy.
Doshi RR; Fortun JA; Kim BT; Dubovy SR; Rosenfeld PJ
Am J Ophthalmol; 2014 Jun; 157(6):1291-1298.e3. PubMed ID: 24582991
[TBL] [Abstract][Full Text] [Related]
17. Multifocal electroretinography in patients with macular telangiectasia type 2.
Goel N; Kumari A; Kumar S; Mehta A
Doc Ophthalmol; 2020 Aug; 141(1):15-21. PubMed ID: 31912262
[TBL] [Abstract][Full Text] [Related]
18. Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2.
Mueller S; Gunnemann F; Rothaus K; Book M; Faatz H; Bird A; Pauleikhoff D
Br J Ophthalmol; 2021 Apr; 105(4):573-576. PubMed ID: 33414243
[TBL] [Abstract][Full Text] [Related]
19. Multicolor imaging in macular telangiectasia-a comparison with fundus autofluorescence.
Govindahari V; Fraser-Bell S; Ayachit AG; Invernizzi A; Nair U; Nair DV; Lupidi M; Singh SR; Rajendran A; Zur D; Gallego-Pinazo R; Marco RD; Cagini C; Cozzi M; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2020 Nov; 258(11):2379-2387. PubMed ID: 32803329
[TBL] [Abstract][Full Text] [Related]
20. Associations between autofluorescence abnormalities and visual acuity in idiopathic macular telangiectasia type 2: MacTel project report number 5.
Balaskas K; Leung I; Sallo FB; Clemons TE; Bird AC; Peto T
Retina; 2014 Aug; 34(8):1630-6. PubMed ID: 24743635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
